Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder

References

• World Health Organization. Depression and other common mental disorders-global health estimates. 2017; Available from: http://apps.who.int/iris/bitstream/10665/254610/1/WHO-MSD-MER-2017.2-eng.pdf. Accessed 529, 2019.
   Google Scholar
• Rai D, Zitko P, Jones K, Lynch J, Araya R. Country-and individual-level socioeconomic determinants of depression: multilevel cross-national comparison. Br J Psychiatry. 2013;202(3):195–203. doi:10.1192/bjp.bp.112.11248223349294
   PubMedGoogle Scholar
• Greenberg PE, Fournier -A-A, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76(2):155–162. doi:10.4088/JCP.14m0929825742202
   PubMed Web of Science ®Google Scholar
• Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013;10(11):e1001547. doi:10.1371/journal.pmed.100154724223526
   PubMed Web of Science ®Google Scholar
• Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–1259. doi:10.1016/S0140-6736(17)32154-228919117
   PubMed Web of Science ®Google Scholar
• Merikangas KR, Ames M, Cui L, et al. The impact of comorbidity of mental and physical conditions on role disability in the US adult household population. Arch Gen Psychiatry. 2007;64(10):1180–1188. doi:10.1001/archpsyc.64.10.118017909130
   PubMedGoogle Scholar
• Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice guideline for the treatment of patients with major depressive disorder third edition. Am J Psychiatry. 2010;167(10):1.20068118
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR* D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40. doi:10.1176/appi.ajp.163.1.2816390886
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231–1242. doi:10.1056/NEJMoa05296316554525
   PubMed Web of Science ®Google Scholar
• National Institute of Mental Health. Questions and answers about the NIMH Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study – all medication levels. 2006; Available from: https://www.nimh.nih.gov/funding/clinical-research/practical/stard/allmedicationlevels.shtml. Accessed 5 29, 2019.
   Google Scholar
• Mauskopf JA, Simon GE, Kalsekar A, Nimsch C, Dunayevich E, Cameron A. Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder. Depress Anxiety. 2009;26(1):83–97. doi:10.1002/da.v26:118833573
   PubMed Web of Science ®Google Scholar
• Knoth RL, Bolge SC, Kim E, Tran Q-V. Effect of inadequate response to treatment in patients with depression. Am J Manag Care. 2010;16(8):e188–e196.20690785
   PubMed Web of Science ®Google Scholar
• Russell JM, Hawkins K, Ozminkowski RJ, et al. The cost consequences of treatment-resistant depression. J Clin Psychiatry. 2004;65(3):341–347. doi:10.4088/JCP.v65n030915096073
   PubMed Web of Science ®Google Scholar
• Suppes T, Silva R, Cucchiaro J, et al. Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2015;173(4):400–407. doi:10.1176/appi.ajp.2015.1506077026552942
   PubMedGoogle Scholar
• Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015;76(9):1224–1231. doi:10.4088/JCP.14m0968826301701
   PubMed Web of Science ®Google Scholar
• Wang P, Si T. Use of antipsychotics in the treatment of depressive disorders. Shanghai Arch Psychiatry. 2013;25(3):134.24991148
   PubMedGoogle Scholar
• Shelton RC, Papakostas GI. Augmentation of antidepressants with atypical antipsychotics for treatment‐resistant major depressive disorder. Acta Psychiatr Scand. 2008;117(4):253–259. doi:10.1111/acp.2008.117.issue-418190674
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry. 2007;68:826–831. doi:10.4088/JCP.v68n060217592905
   PubMed Web of Science ®Google Scholar
• Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980–991. doi:10.1176/appi.ajp.2009.0903031219687129
   PubMed Web of Science ®Google Scholar
• Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S. Second‐generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev. 2010;(12):CD008121.21154393
   PubMedGoogle Scholar
• Chen J, Gao K, Kemp DE. Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Curr Opin Psychiatry. 2011;24(1):10–17. doi:10.1097/YCO.0b013e328341350521088586
   PubMed Web of Science ®Google Scholar
• Seetasith A, Greene M, Hartry A, Burudpakdee C. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder. J Med Econ. 2018;21(9):888–901. doi:10.1080/13696998.2018.148437329862860
   PubMed Web of Science ®Google Scholar
• Yermilov I, Greene M, Chang E, Hartry A, Yan T, Broder MS. Earlier versus later augmentation with an antipsychotic medication in patients with major depressive disorder demonstrating inadequate efficacy in response to antidepressants: a retrospective analysis of US claims data. Adv Ther. 2018;35(12):2138–2151. doi:10.1007/s12325-018-0838-230456519
   PubMedGoogle Scholar
• Prescribing information for Abilify. Otsuka American Pharmaceutical, Inc., Rockville, MD.
   Google Scholar
• Prescribing information for Seroquel XR. AstraZeneca Pharmaceuticals LP., Wilmington, DE.
   Google Scholar
• Prescribing information for Rexulti. Otsuka American Pharmaceutical, Inc., Rockville, MD.
   Google Scholar
• Maeda K, Lerdrup L, Sugino H, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):605–614. doi:10.1124/jpet.114.21381924947464
   PubMed Web of Science ®Google Scholar
• Das S, Barnwal P, Winston AB, Mondal S, Saha I. Brexpiprazole: so far so good. Ther Adv Psychopharmacol. 2016;6(1):39–54. doi:10.1177/204512531561473926913177
   PubMed Web of Science ®Google Scholar
• Peuskens J. The management of schizophrenia: focus on extended-release quetiapine fumarate. Neuropsychiatr Dis Treat. 2011;7:549. doi:10.2147/NDT22003295
   PubMed Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424. doi:10.1080/00273171.2011.56878621818162
   PubMed Web of Science ®Google Scholar
• Brookhart MA, Wyss R, Layton JB, Stürmer T. Propensity score methods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes. 2013;6(5):604–611. doi:10.1161/CIRCOUTCOMES.113.00035924021692
   PubMed Web of Science ®Google Scholar
• Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med. 1991;10(4):577–581. doi:10.1002/(ISSN)1097-02582057656
   PubMedGoogle Scholar
• Kluwer W Medi-span price Rx. Available from: https://www.wolterskluwercdi.com/price-rx/. Accessed 5 29, 2019.
   Google Scholar
• Wu EQ, Greenberg PE, Ben-Hamadi R, Yu AP, Yang EH, Erder MH. Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram. Am Health Drug Benefits. 2011;4(2):78.25126340
   PubMedGoogle Scholar
• World Health Organization. Mental health of older adults. 2017; Available from: http://www.who.int/mediacentre/factsheets/fs381/en/. Accessed 529, 2019..
   Google Scholar
• Kramer D, Allgaier A-K, Fejtkova S, Mergl R, Hegerl U. Depression in nursing homes: prevalence, recognition, and treatment. Int J Psychiatry Med. 2009;39(4):345–358. doi:10.2190/PM.39.4.a20391857
   PubMed Web of Science ®Google Scholar
• Richardson LP, DiGiuseppe D, Garrison M, Christakis DA. Depression in Medicaid-covered youth: differences by race and ethnicity. Arch Pediatr Adolesc Med. 2003;157(10):984–989. doi:10.1001/archpedi.157.10.98414557159
   PubMed Web of Science ®Google Scholar
• Centers of Medicare & Medicaid Services. Physician and mental health condition prevalence and comorbidity among fee-for-service medicare-medicaid enrollees. 2014; Available from: https://www.cms.gov/Medicare-Medicaid-Coordination/Medicare-and-Medicaid-Coordination/Medicare-Medicaid-Coordination-Office/Downloads/Dual_Condition_Prevalence_Comorbidity_2014.pdf. Accessed 529, 2019..
   Google Scholar
• Mansournia MA, Hernán MA, Greenland S. Matched designs and causal diagrams. Int J Epidemiol. 2013;42(3):860–869. doi:10.1093/ije/dyt08323918854
   PubMed Web of Science ®Google Scholar
• Heinze G, Jüni P. An overview of the objectives of and the approaches to propensity score analyses. Eur Heart J. 2011;32(14):1704–1708. doi:10.1093/eurheartj/ehr03121362706
   PubMed Web of Science ®Google Scholar
• Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology (Cambridge, Mass). 2009;20(4):488. doi:10.1097/EDE.0b013e3181a819a1
   PubMed Web of Science ®Google Scholar
• Porta M. A Dictionary of Epidemiology. Oxford university press; 2014.
   Google Scholar
• Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. Vol. 3 Wolters Kluwer Health/Lippincott Williams & Wilkins Philadelphia; 2008.
   Google Scholar
• Brookhart MA, Stürmer T, Glynn RJ, Rassen J, Schneeweiss S. Confounding control in healthcare database research: challenges and potential approaches. Med Care. 2010;48(60):S114. doi:10.1097/MLR.0b013e3181dbebe320473199
   PubMedGoogle Scholar
• Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a monte carlo study. Stat Med. 2007;26(4):734–753. doi:10.1002/(ISSN)1097-025816708349
   PubMed Web of Science ®Google Scholar
• Fewell Z, Davey Smith G, Sterne JA. The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study. Am J Epidemiol. 2007;166(6):646–655. doi:10.1093/aje/kwm16517615092
   PubMed Web of Science ®Google Scholar